These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38497600)

  • 1. Biomimetic Nanovehicle-Enabled Targeted Depletion of Intratumoral
    Geng S; Guo P; Li X; Shi Y; Wang J; Cao M; Zhang Y; Zhang K; Li A; Song H; Zhang Z; Shi J; Liu J; Yang Y
    ACS Nano; 2024 Mar; 18(12):8971-8987. PubMed ID: 38497600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial Fusobacterium nucleatum-Mimicking Nanomedicine to Selectively Eliminate Tumor-Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer.
    Chen L; Zhao R; Shen J; Liu N; Zheng Z; Miao Y; Zhu J; Zhang L; Wang Y; Fang H; Zhou J; Li M; Yang Y; Liu Z; Chen Q
    Adv Mater; 2023 Nov; 35(45):e2306281. PubMed ID: 37722134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
    Gao Y; Bi D; Xie R; Li M; Guo J; Liu H; Guo X; Fang J; Ding T; Zhu H; Cao Y; Xing M; Zheng J; Xu Q; Xu Q; Wei Q; Qin H
    Signal Transduct Target Ther; 2021 Nov; 6(1):398. PubMed ID: 34795206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer.
    Gao Y; Zou T; Xu P; Wang Y; Jiang Y; Chen YX; Chen H; Hong J; Fang JY
    Neoplasia; 2023 Jan; 35():100850. PubMed ID: 36371909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer.
    Jiang SS; Xie YL; Xiao XY; Kang ZR; Lin XL; Zhang L; Li CS; Qian Y; Xu PP; Leng XX; Wang LW; Tu SP; Zhong M; Zhao G; Chen JX; Wang Z; Liu Q; Hong J; Chen HY; Chen YX; Fang JY
    Cell Host Microbe; 2023 May; 31(5):781-797.e9. PubMed ID: 37130518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ways Fusobacterium nucleatum translocate to breast tissue and contribute to breast cancer development.
    Guo X; Yu K; Huang R
    Mol Oral Microbiol; 2024 Feb; 39(1):1-11. PubMed ID: 38171827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.
    Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G
    Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusobacterium nucleatum carcinogenesis and drug delivery interventions.
    Chen Z; Huang L
    Adv Drug Deliv Rev; 2024 Jun; 209():115319. PubMed ID: 38643839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size-tunable nanogels for cascaded release of metronidazole and chemotherapeutic agents to combat Fusobacterium nucleatum-infected colorectal cancer.
    Xie S; Wei L; Liu Y; Meng J; Cao W; Qiu B; Li X
    J Control Release; 2024 Jan; 365():16-28. PubMed ID: 37956925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
    Nosho K; Sukawa Y; Adachi Y; Ito M; Mitsuhashi K; Kurihara H; Kanno S; Yamamoto I; Ishigami K; Igarashi H; Maruyama R; Imai K; Yamamoto H; Shinomura Y
    World J Gastroenterol; 2016 Jan; 22(2):557-66. PubMed ID: 26811607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of
    Zhang N; Liu Y; Yang H; Liang M; Wang X; Wang M; Kong J; Yuan X; Zhou F
    Pathol Oncol Res; 2021; 27():1609846. PubMed ID: 34305476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
    Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
    Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
    J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.